Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379858 | 0.89 | ADAM17 (0.48) | PPARGPPARAPPARDADAM17MAPT | |
| SCHEMBL3382165 | 0.88 | PPARG (0.49) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL3384312 | 0.82 | PPARA (0.51) | PPARGPPARAPPARDMAPTFFAR1 | |
| SCHEMBL4191222 | 0.81 | PPARG (0.46) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL6386838 | 0.81 | MTNR1A (0.45) | CYP2D6 | |
| SCHEMBL4901438 | 0.79 | NR1H2 (0.38) | PPARGPPARAPPARDMAPT | |
| SCHEMBL4190574 | 0.77 | ADAM17 (0.45) | PPARGPPARAPPARDADAM17FFAR1 | |
| SCHEMBL1123058 | 0.77 | MAPT (0.62) | PPARGPPARAPPARDADAM17MAPT | |
| SCHEMBL4902726 | 0.77 | NR1H2 (0.35) | PPARGPPARAPPARDMAPTFFAR1 | |
| SCHEMBL3379870 | 0.75 | SMN1; SMN2 (0.47) | PPARGMAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572180-B1 | USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2009-02-25 | — | — | EP | claimed |
| US-7375124-B2 | Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-20 | — | — | US | claimed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | claimed |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-13 | — | — | US | claimed |
| EP-1572180-A1 | USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056355-A1 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-08 | — | — | WO | claimed |
| EP-1474387-B1 | DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-24 | — | — | EP | disclosed |
| EP-1572180-B1 | USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-7375124-B2 | Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-20 | — | — | US | disclosed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | disclosed |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-13 | — | — | US | disclosed |
| EP-1572180-A1 | USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-14 | — | — | EP | disclosed |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P. A | 2005-03-10 | — | — | US | disclosed |
| WO-2004056355-A1 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PPARD 2/4885 |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | LIPC, HMGCR, PNLIP | PPARG 225/4885PPARA 88/4885PPARD 285/4885 |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.